Brief: Clinuvel Pharmaceuticals Says Philippe Wolgen Returns As MD
13/06/2025 01:29
June 13 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX: PHILIPPE WOLGEN RETURNS AS MANAGING DIRECTOR LACHLAN HAY TO CONTINUE AS ACTING CEO UNTIL SEPTEMBER 2025 Further company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist